BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 2145022)

  • 1. Recent advances in the treatment of B-cell chronic lymphocytic leukemia.
    Cheson BD
    Oncology (Williston Park); 1990 Sep; 4(9):71-8, 83-4; disc. 84, 87-8, 90 pass. PubMed ID: 2145022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pentostatin (Nipent) and chlorambucil with granulocyte-macrophage colony-stimulating factor support for patients with previously untreated, treated, and fludarabine-refractory B-cell chronic lymphocytic leukemia.
    Waselenko JK; Grever MR; Beer M; Lucas MA; Byrd JC
    Semin Oncol; 2000 Apr; 27(2 Suppl 5):44-51. PubMed ID: 10877052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of chronic lymphocytic leukemia.
    Han T; Rai KR
    Hematol Oncol Clin North Am; 1990 Apr; 4(2):431-45. PubMed ID: 2182600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study design in chronic lymphocytic leukemia.
    Cheson BD
    Nouv Rev Fr Hematol (1978); 1988; 30(5-6):407-10. PubMed ID: 3065736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent progress in the management of chronic lymphocytic leukemia.
    Robak T
    Cancer Treat Rev; 2007 Dec; 33(8):710-28. PubMed ID: 17904294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The place of cladribine in the treatment of chronic lymphocytic leukemia: a 10-year experience in Poland.
    Robak T
    Ann Hematol; 2005 Feb; 84(2):63-70. PubMed ID: 15558283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current approaches to the chemotherapy of B-cell chronic lymphocytic leukemia: a review.
    Cheson BD
    Am J Hematol; 1989 Sep; 32(1):72-7. PubMed ID: 2667343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoclonal antibody therapy of chronic lymphocytic leukemia.
    Mavromatis B; Cheson BD
    J Clin Oncol; 2003 May; 21(9):1874-81. PubMed ID: 12721266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current status and future directions of clinical trials in chronic lymphocytic leukemia.
    Nerenstone SR; Archer JI; Cheson BD
    Oncology (Williston Park); 1987 Oct; 1(8):31-40, 44. PubMed ID: 3079490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805.
    Byrd JC; Peterson BL; Gabrilove J; Odenike OM; Grever MR; Rai K; Larson RA;
    Clin Cancer Res; 2005 Jun; 11(11):4176-81. PubMed ID: 15930354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia.
    Faderl S; Rai K; Gribben J; Byrd JC; Flinn IW; O'Brien S; Sheng S; Esseltine DL; Keating MJ
    Cancer; 2006 Sep; 107(5):916-24. PubMed ID: 16832816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2-Chlorodeoxyadenosine (2-CdA) in the treatment of patients with relapsed chronic lymphocytic leukemia.
    Krykowski E; Warzocha K; Robak T
    Arch Immunol Ther Exp (Warsz); 1995; 43(5-6):317-21. PubMed ID: 8744653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High dose chlorambucil versus Binet's modified cyclophosphamide, doxorubicin, vincristine, and prednisone regimen in the treatment of patients with advanced B-cell chronic lymphocytic leukemia. Results of an international multicenter randomized trial. International Society for Chemo-Immunotherapy, Vienna.
    Jaksic B; Brugiatelli M; Krc I; Losonczi H; Holowiecki J; Planinc-Peraica A; Kusec R; Morabito F; Iacopino P; Lutz D
    Cancer; 1997 Jun; 79(11):2107-14. PubMed ID: 9179056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of chronic lymphatic leukemia].
    Adam Z; Vorlícek J; Hejlová N
    Vnitr Lek; 1996 Aug; 42(8):573-8. PubMed ID: 8967031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized phase II trial of high-dose chlorambucil vs. fludarabine in patients with advanced B-chronic lymphocytic leukemia. EORTC Leukemia Cooperative Group.
    Hematol Cell Ther; 1999 Jun; 41(3):127-36. PubMed ID: 10456443
    [No Abstract]   [Full Text] [Related]  

  • 16. Fludarabine treatment in B-cell chronic lymphocytic leukemia: response, toxicity and survival analysis in 47 cases.
    Stelitano C; Morabito F; Kropp MG; Callea V; Iuliano F; Oriana V; Levato D; Nobile F; Molica S; Brugiatelli M
    Haematologica; 1999 Apr; 84(4):317-23. PubMed ID: 10190945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic features and therapeutical approaches in B-cell chronic lymphocytic leukemia: an update.
    Molica S; De Rossi G; Luciani M; Levato D
    Haematologica; 1995; 80(2):176-93. PubMed ID: 7628755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bendamustine in the treatment of chronic lymphocytic leukemia.
    Knauf W
    Expert Rev Anticancer Ther; 2009 Feb; 9(2):165-74. PubMed ID: 19192955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bendamustine: a new treatment option for chronic lymphocytic leukemia.
    Glode AE; Jarkowski A
    Pharmacotherapy; 2009 Nov; 29(11):1375-84. PubMed ID: 19857152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of fludarabine, cyclophosphamide/doxorubicin/prednisone, and cyclophosphamide/doxorubicin/vincristine/prednisone in advanced forms of chronic lymphocytic leukemia: preliminary results of a controlled clinical trial. The French Cooperative Group on Chronic Lymphocytic Leukemia.
    Semin Oncol; 1993 Oct; 20(5 Suppl 7):21-3. PubMed ID: 8235691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.